Prifetrastat

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NamePrifetrastat
Drug Alias NamePF-07248144
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone acetyltransferase KAT6A inhibitorsHistone acetyltransferase KAT6B inhibitors
TargetsHistone acetyltransferase KAT6AHistone acetyltransferase KAT6B
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[31] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Investment Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A